The alloimmunized patient: Monitoring and therapeutics

American Journal of the Medical Sciences

Volumn 313, Issue 5, 1997, Pages 279-282

  Braun, William E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alloimmunization therapy; Anti human leukocyte antigen (anti HLA) antibodies; Crossmatch; Monitoring alloimmunized patients; Sensitization

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC ANTIBODY; HLA ANTIBODY; IMMUNOGLOBULIN; OKT 3;

ALLOIMMUNIZATION; ARTICLE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HLA MATCHING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; PATIENT MONITORING; PLASMAPHERESIS;

EID: 0030994621     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199705000-00006     Document Type: Article

References (23)

1. Scornik JC, Ireland JE, Howard RJ, Pfaff WW. Assessment of the risk for broad sensitization by blood transfusions. Transplantation. 1984;37:249-53.
2. Birmingham DJ, Shen X-P, Hartman JA, Dillon JJ, Hebert LA. Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients. Kidney Int. 1996;50:543-9.
3. Braun WE. Donor-specific antibodies: Clinical relevance of antibodies detected in lymphocyte crossmatches. Clin Lab Med. 1991;11:571-602.
4. Lederer SR, Schneeberger H, Albert E, Johnson JP, Gruber R, Land W, et al. Early renal graft dysfunction: The role of preformed antibodies to DR-typed lymphoblastoid cell lines. Transplantation. 1996;61:313-9.
5. Yard B, Spruyt-Gerritse M, Claas F, Thorogood J, Bruijn JA, Paape ME, et al. The clinical significance of allospe- cific antibodies against endothelial cells detected with an antibody-dependent cellular cytotoxicity assay for vascular rejection and graft loss after renal transplantation. Transplantation. 1993;55:1287-93.
6. Cardella CJ, Falk JA, Nicholson MJ, Harding M, Cook GT. Successful renal transplantation in patients with T-cell reactivity to donor. Lancet. 1982;2:1240-3.
7. Mahoney RJ, Norman DJ, Colombe BW, Garovoy MR, Leeber DA. Identification of high-and low-risk second kidney grafts. Transplantation. 1996;61:1349-55.
8. Kerman RH, Kimball PM, Van Buren CT, Lewis RM, Kahan BD. Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation. 1991; 51:338-42.
9. Cecka JM, Terasaki PI. Repeating HLA antigen mismatches in renal retransplants - a second-class mistake? Transplantation. 1994;57:515-9.
10. Opelz G. For the Collaborative Transplant Study. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation. 1995;60:1220-4.
11. Taube DH, Williams DG, Cameron JS, Bewick M, Ogg CS, Rudge CJ, et al. Renal transplantation after removal and prevention of resynthesis of HLA antibodies. Lancet. 1984;1:824-8.
12. Palmer A, Taube D, Welsh K, Bewick M, Gjorstrup P, Thick M. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet. 1989;1:10-2.
13. Hakim RM, Milford E, Himmelfarb J, Wingard R, Lazarus JM, Watt RM. Extracorporeal removal of anti-HLA antibodies in transplant candidates. Am J Kidney Dis. 1990;16:423-31.
14. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol. 1989;143:4104-9.
15. Toyoda M, Zhang XM, Petrosian A, Wachs K, Moudgil A, Jordan SC. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma globulin. Transpl Immunol. 1994;2:337-41.
16. Glotz D, Haymann JP, Sansonetti N, Francois A, Menoyo-Calonge V, Bariety J, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVlg). A potential tool for transplantation of immunized patients. Transplantation. 1993;56:335-7.
17. Czer L, Jordan SC, Tyan D, Valenza M, Admon D, Barath P, et al. Novel approach to treatment of patients with cytotoxic antibodies after heart transplantation: Use of intravenous immunoglobulin. Circulation. 1993;88:I94.
18. Tyan D, Li V, Czer L, Trento A, Jordan SC. IVIG suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation. 1994;57:553-62.
19. Glotz D, Haymann JP, Niaudet P, Lang P, Druet P, Bariety J. Successful kidney transplantation of immunized patients after desensitization with normal polyclonal immunoglobulins. Transplant Proc. 1995;27:1038-9.
20. Jordan SC. Sensitization: Potential solutions. Presented at the American Society of Transplant Physicians, 15th Annual Meeting, May 27, 1996; Dallas, TX.
21. Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response, II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation. 1992;53:550-5.
22. Trpkov K, Campbell P, Pazderka F, Cockfield S, Solez K, Halloran PF. Pathologic features of acute renal allograft rejection associated with donor-specific antibody: Analysis using the Banff grading schema. Transplantation. 1996; 61:1586-92.
23. Reed EF, Hong B, Ho E, Harris PE, Weinberger J, Suciu-Foca N. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Transplantation. 1996;61:566-72.